Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 3/20 | 0.39 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492995 | 1.00 | INPP5A (0.39) | INPP5AITPR2ITPR3ITPR1SMPD1 | |
| SCHEMBL10023962 | 1.00 | INPP5A (0.39) | INPP5AITPR2ITPR3ITPR1SMPD1 | |
| SCHEMBL19464721 | 1.00 | INPP5A (0.39) | INPP5AITPR2ITPR3ITPR1SMPD1 | |
| SCHEMBL432511 | 1.00 | INPP5A (0.39) | INPP5AITPR2ITPR3ITPR1SMPD1 | |
| SCHEMBL21553519 | 0.86 | — | — | |
| SCHEMBL8135883 | 0.84 | — | — | |
| SCHEMBL24869814 | 0.83 | — | — | |
| SCHEMBL15281151 | 0.83 | — | — | |
| SCHEMBL16921641 | 0.83 | — | — | |
| SCHEMBL14930895 | 0.82 | FBP1 (0.46) | INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10781449-B2 | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| CN-103917647-B | Methods and compositions for neuroprotection | 夸克制药公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-3276004-B1 | METHODS FOR TREATING CHRONIC KIDNEY DISEASE | QUARK PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-106701758-B | Modulation of HSP47 expression | 日东电工株式会社 | 2020-02-07 | — | — | CN | disclosed |
| EP-2504435-B1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10421962-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190040385-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TARGETING P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-2268316-A2 | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 | Quark Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010144336-A2 | METHODS FOR TREATING CHRONIC KIDNEY DISEASE | QUARK PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010111198-A1 | COMPOUNDS COMPOSITIONS AND METHODS OF TREATING CANCER AND FIBROTIC DISEASES | QUARK PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2231168-A2 | NOVEL SIRNA STRUCTURES | Quark Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010048352-A2 | METHODS FOR TREATING EYE DISORDERS | QUARK PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009147684-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF EAR DISORDERS | QUARK PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009144704-A2 | siRNA COMPOUNDS FOR INHIBITING NRF2 | QUARK PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009116037-A2 | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 | QUARK PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009074990-A2 | RTP801L SIRNA COMPOUNDS AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009044392-A2 | NOVEL SIRNA STRUCTURES | QUARK PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | HSPH1, FABP1, LRAT | INPP5A 4254/4885ITPR2 3752/4885ITPR3 3122/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | INPP5A 4005/4885ITPR2 3601/4885ITPR3 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.